All posts by imreal

How to Accelerate Lupus Solutions with RWD, Upcoming Webinar Hosted by Xtalks


  • Demographic and socioeconomic data
  • Deep clinical information on disease manifestations
  • Health care utilization, including treatment information
  • Long-term clinical outcomes, including patient-reported outcomes (PROs)

Join Alira Health’s Real World Solutions experts and external partners from FORWARD — the US national databank for rheumatic diseases — for a deep dive into Lupus RWD.

Join Dr. Kaleb Michaud, Professor, Division of Rheumatology, Director, Rheumatology Fellowship Research Program, University of Nebraska Medical Center; Dr. Patti Katz, Professor, Medicine, University of California San Francisco; and Frederico Calado, Vice President, Global Real-World Solutions, Alira Health, for the live webinar on Monday, December 18, 2023, at 11am EST (4pm GMT/UK).

For more information, or to register for this event, visit How to Accelerate Lupus Solutions with RWD.

To learn more about the Alira Health partnership with FORWARD, visit Alira Health and FORWARD Launch Enhanced Lupus Patient Registry, Accelerating Solutions for Patients.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Media Contact

Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, vkovacevic@xtalks.com

SOURCE Xtalks

Ideal Option Opens Largest Addiction Medicine Center in Yakima


The new, high-capacity clinic will vastly increase the number of individuals in active treatment and recovery from substance use disorder.

YAKIMA, Wash., Dec. 4, 2023 /PRNewswire-PRWeb/ — Ideal Option, a national leader in evidence-based outpatient treatment for addiction to fentanyl, heroin, methamphetamine, alcohol and polysubstance, has opened a new addiction medicine center in Yakima.

The new center merges their two existing Yakima clinics at 11th Ave and River Rd into one location at 602 N 39th Ave. Located in the same building as Yakima County Medical Society, the center is staffed with three addiction medicine providers and five medical assistants and patients receive support from a peer outreach specialist. With capacity to see up to 75 patients per day, the clinic is the largest of its kind in Yakima.

A trusted, low-barrier provider in Yakima for over 10 years, Ideal Option carries no waitlists, accepts Medicaid and serves all patients with respect and dignity. Ideal Option providers are experts in treating high-risk patients who need specialized protocols for complex drug combinations or health conditions such as pregnancy and chronic disease.

Ideal Option data support the effectiveness of medication-assisted treatment for opioid use disorder. Among Washington state patients who continued treatment with Ideal Option throughout 2022, urine drug testing revealed a remarkable 98% reduction in fentanyl use and a 94% reduction in total opioid use.

With the recent expansion of its in-house laboratory capabilities, Ideal Option is now able to detect dozens of fentanyl analogs, nitazines, novel psychoactive substances, and cutting agents such as xylazine and lidocaine – information used to guide personalized treatment plans.

According to data from the Yakima County Coroner’s Office, 98 residents died of a drug overdose last year, a 34% increase from the 73 deaths reported in 2020. Of the overdose deaths that occurred in 2020 and 2021, more than 60% involved opioids, with fentanyl being the most common opioid involved in those deaths.

“Yakima has been hit particularly hard by the street drug epidemic, so a high-capacity centralized, low-barrier resource like this is desperately needed,” said Tyler Vermillion, Ideal Option community outreach coordinator for Eastern Washington. “We hope this beautiful new center will help to normalize treatment and encourage more people suffering from substance use disorder in Yakima County to begin their recovery and reclaim their lives.”

The new treatment center in Yakima is open Monday – Thursday, 7:00 a.m. – 6 p.m. at 602 N 39th Ave, Ste. 200.

Most forms of insurance are accepted, including Medicare and Medicaid, and patients can typically get started on treatment for fentanyl, heroin, alcohol or other substances within 1-3 business days.

Ideal Option’s offices on 11th Ave and River Rd have now closed.

Patients can make an appointment by calling 1.877.522.1275 or visiting‥www.idealoption.com.

About Ideal Option

Headquartered in Kennewick, Washington, Ideal Option was founded in 2012 and has since helped more than 75,000 patients through a network of 89 office-based medication-assisted treatment (MAT) clinics across 9 states. With a mission to serve under-served communities, Ideal Option accepts most forms of insurance including Medicaid and Medicare. Financial assistance and payment plans are also available.

Ideal Option’s team of medical providers carry certifications in Addiction and Emergency Medicine, Internal, and Family Medicine, among other specialties. The company also employs social workers, caseworkers, counselors, and mental health practitioners. This holistic approach helps drive positive outcomes, including family stability, stable housing, improved overall health, and reduced rates of recidivism.

In all the communities it serves, Ideal Option collaborates with existing stakeholders and providers to improve the continuum of care. This approach includes partnerships with emergency rooms and county jail systems, where individuals with substance use disorder often appear, as well as collaborating with numerous support agencies and municipal programs addressing social needs such as housing, mental health, and nutrition support.

Media Contact

Olivia Roe, Ideal Option, 1 9199466644, [email protected], www.idealoption.com

Twitter, Facebook, LinkedIn

SOURCE Ideal Option



Claire Fair Joins Cardiovascular Logistics as the Company’s Chief People Officer


“We’re thrilled to welcome Claire to Cardiovascular Logistics. She is an exceptionally talented human resources leader who brings a unique passion for driving change and transformation, improving performance, and supporting the goals of high-growth organizations in the healthcare and service industries,” said David Konur, CEO of Cardiovascular Logistics. “Her strong ability to collaborate between business and human resources to steer company strategy and direction will be instrumental in meeting our evolving business needs and positioning us for sustained growth.”

Fair comes to Cardiovascular Logistics with a wealth of experience, having served as the Senior Vice President and Chief People Officer at Pediatrix Medical Group for 21 years. During her tenure, she contributed to the growth of the organization from 1,400 to 15,000 employees, led the cultural integration of acquired physician practices and new specialties, championed diversity initiatives, and hired the first diversity, equity, and inclusion leader in the organization. Before her role at Pediatrix Medical Group, Fair served as the Vice President of Human Resources for Perfumania, leading the HR function as the company grew from 125 stores and became the nation’s largest discount retailer of fragrances, cosmetics, and related products with approximately 265 stores, an e-retail site, and a workforce of more than 1600 employees.

“Cardiovascular disease is on the rise, driven by factors such as the aging population, rising obesity rates, and individuals grappling with the long-haul effects of COVID-19. With its rapidly expanding national platform, Cardiovascular Logistics has the incredible potential to ensure cardiovascular patients receive the highest quality of care,” said Fair. “I’m excited to join this exceptional organization at this foundational stage and look forward to contributing to the well-being of thousands of patients by supporting our most valuable asset—our people.”

Fair holds a bachelor’s degree in Fashion Merchandising/Retail Management from Central Washington University in Ellensburg, Wash.

About Cardiovascular Logistics

Cardiovascular Logistics (CVL) is the most comprehensive cardiovascular platform in the country. Formed in 2013, CVL is integrating the nation’s best cardiology practices into one robust cardiovascular solution. CVL is fundamentally changing how cardiovascular care is delivered in the United States. The CVL platform is grounded in the mission of providing patients with the highest quality of cardiovascular care available. CVL partners with Lee Equity Partners, a New York-based private equity firm. For more information, visit www.cardiovascularlogistics.com.

Media Contact

Elizabeth Mars, Marketri, 1 303.955.0319, [email protected], www.marketri.com

SOURCE Cardiovascular Logistics

CarrTech Corp. Poised to Reduce Needle Sticks & Glass Shard Contamination in Medications


More than 50% of medical solutions are packaged in glass ampoules globally. Medical professionals must break the glass to access medications, risking the introduction of glass shards into the liquid – and ultimately patients. The current two-needle, multi-step filtration process is cumbersome, especially when seconds count.

As Carr explains, “every time you touch the needle there is an increased risk of sepsis and a needle stick.” She calculates that the time invested in calling out HAZMAT teams and processing reports related to such needle sticks saps about $5B from hospitals annually. Then there’s insurance and liability. That’s above and beyond the human cost in pain and suffering if jagged glass microparticles are inadvertently injected into a patient.

Kathie Callahan Brady is FITCI’s CEO and a CarrTech advisor. “Taking a medical device from concept to marketplace can be a steep climb, but Sue and her team are truly dedicated. They understand what a huge impact this product will have on people and industry.”

According to CarrTech’s research, FROG, has reasonable commercial potential to become the new standard of care for the $6B global filter market (growing at a CAGR of 9.9%), facilitating the use of more than six billion disposable glass ampoules each year.

In 2023 the company also made progress in its sterilization and bioburden testing, performed human factor studies, engaged Becton Dickinson as a strategic partner, and created an “instruction for use” video. In early 2024, the CarrTech will expand into FITCI’s new entrepreneurial innovation center, the EDGE@321 in the City of Frederick, MD.

Callahan Brady says, “This is an incredibly exciting time for CarrTech. Investors and industry leaders are paying attention. And we can’t wait to see how much they will accomplish in 2024.”

About CarrTech

CarrTech is a medical technology company and inventor of the FROG™ (Filter Removal of Glass) device. FROG combines the traditional multi-step, two needle process of filtering glass particles from medicines into a single step with an all-in-one needle that is safer, faster, greener, and more efficient for healthcare providers. http://www.carrtechcorp.com

See the F.R.O.G. video on YouTube at https://www.youtube.com/watch?v=7_PwSFCoAVU

About FITCI

FITCI, the Frederick Innovative Technology Center, Inc., fosters entrepreneurial activity in Frederick, Maryland’s science and technology industries, including early-stage life science, IT, Agtech, renewable energy and related business sectors. Its purpose is to enable emerging entrepreneurs, encourage innovation, and accelerate development of commercially viable businesses that contribute to a healthy economy through coaching, connections, and equitable access to resources within a collaborative community environment. http://www.fitci.org

About QMBCs

The Maryland Department of Commerce Biotechnology Investment Incentive Tax Credit (BIITC) provides an income tax credit equal to 33% of an eligible investment in a Qualified Maryland Biotechnology Company (QMBC) up to $250,000 in tax credits, or 50% of an eligible investment in a QMBC up to $500,000 in tax credits if the QMBC is located in Allegany, Dorchester, Garrett or Somerset County.

Read more about safety concerns with glass particle contamination at https://pubmed.ncbi.nlm.nih.gov/34101800/

Media Contact

Sue E. Carr RPh., President and Founder, CarrTech Corp., 240-620-2309, [email protected], http://www.carrtechcorp.com

Kathie Callahan Brady, CEO, FITCI, 301-694-2999, [email protected], www.fitci.org

SOURCE CarrTech Corp.

Cytonus Secures Series A Financing to Advance Pipeline of Novel Cargocyte™-based Medicines


“Jae has been a visionary champion in shaping the current round, and his support will help accelerate the development of Cytonus as we work together to bring the company’s proprietary Cargocyte Drug Delivery Platform to usher in a new era of precision medicine,” commented Cytonus’ Chief Executive Officer and co-founder, Remo Moomiaie-Qajar, MD.

“It is a great privilege to be joined by Professor Bell, who is a thought leader and major contributor to the field of modern viral immunotherapeutics.” commented Cytonus’ Chief Scientific Innovator and co-founder, Richard Klemke, PhD.

“We are grateful for the enthusiastic support from such a prestigious group of investors, which reflects the progress of our Cargocyte Drug Delivery Platform in advancing a pipeline of first-in-class programs for delivering well-validated therapeutics to difficult-to-reach tissues,” commented Cytonus’ executive chairman, Christopher Thorne, JD-MBA, “The combination of the company’s robust pipeline, novel platform technology, and highly talented team identifies Cytonus as an attractive opportunity with an exciting future.”

About Cytonus

Cytonus Therapeutics, Inc. is a San Diego-based biotechnology company focused on discovering and advancing novel medicines enabled by the Cargocyte™ Drug Delivery Platform. The company has developed a vast pipeline of proprietary immunotherapeutic products to improve patient outcomes for a wide range of medical conditions including cancers, infectious diseases, inflammatory diseases, and cognitive disorders. The Cargocyte-based technologies are next-generation synthetic biology delivery drones that have demonstrated measurable advantages for treating numerous medical applications across unmet therapeutic areas. Cargocytes™ are engineered to safely transport a multiplicity of therapeutic payloads into difficult-to-reach targeted tissues, and can be programmed to deliver selective, potent, and controllable “off-the-shelf” well-validated therapies. These distinctive features demonstrate the potential for Cargocytes to usher in a new era of precision medicine.

For more information, please visit https://cytonus.com. Follow Cytonus on LinkedIn and Twitter “X”: @CytonusTx.

Notice: Statements in this news release, other than strictly historical facts, such as statements about Cytonus’ plans and strategies, new and existing products, and technologies, anticipated clinical and regulatory pathways, and markets for its products, are forward-looking statements. The words “believe,” “expect,” “aim,” “anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements that speak only as of the date hereof. Such statements involve risks and uncertainties that could cause actual results to differ materially from anticipated results due to many factors, including regulatory and development risks. The company undertakes no obligation to publicly update or revise any forward-looking statement. This news release is neither an offer to sell, nor the solicitation of any offer to purchase, any security.

Media Contact

Karen M Markham, Cytonus Therapeutics, Inc., 1 14135311559, [email protected], www.cytonus.com

SOURCE Cytonus Therapeutics, Inc.

Rite-Solutions Receives HIRE Vets Platinum Medallion Award 2023


Dedicated to hiring and supporting veterans, Rite-Solutions was among 153 medium-sized companies nationwide that received the Platinum award—the program’s highest tier.

MIDDLETOWN, R.I., Dec. 4, 2023 /PRNewswire-PRWeb/ — Rite-Solutions was recently a recipient of the Platinum HIRE Vets Medallion Award for 2023.

The Honoring Investments in Recruiting and Employing (HIRE) American Military Veterans Act of 2017 established the HIRE Vets Medallion Program which recognizes employers that recruit, hire, retain, and develop veterans. Applications are reviewed annually, and award recipients are notified at a time to coincide with Veterans Day.

This year almost 860 companies received the award. Rite-Solutions is one of 153 medium-sized companies nationwide receiving the Platinum award—the program’s highest tier.

“This is the third year we have applied for and received the HIRE Vets Platinum award,” notes Joe Marino, Founder and CEO of Rite-Solutions. “We are proud to support our nation’s veterans. They bring the same dedication and work ethic to the workplace that they did in service of our country.”

To receive the award, 10% of employees must be veterans. In addition, 10% of new hires must be veterans or 85% of hired veterans must be retained. Companies must also have veteran integration assistance programs designed to support veterans.

“Veterans bring unique experiences, skills, and expertise to Rite-Solutions. We also have a shared passion about serving today’s armed forces and we are honored to win this award” says Susan Borden, Vice President of People Operations at Rite-Solutions.

Rite-Solutions, Inc. is an award-winning small business specializing in system engineering, software development, information technology (IT), and cyber security for government and commercial segments. Rite-Solutions has offices in Rhode Island, Connecticut, and Washington D.C. For more information, please visit https://www.rite-solutions.com.

For more information on the HIRE Vets Medallion Program, please visit https://www.hirevets.gov

Media Contact

John Thornell, Rite-Solutions, 1 8604154882, [email protected], www.rite-solutions.com

SOURCE Rite-Solutions

U.S. Dermatology Partners Relocates Sherman Office to Expanded Facility


Named after General Sidney Sherman, a hero of the Texas Revolution, Sherman, Texas, is the county seat of Grayson County. Sherman is ten miles south of Lake Texoma, one of the largest reservoirs in Texas, well-known for its champion bass fishing, sailing, camping, and hiking. Sherman is also home to Austin College, a private liberal arts college founded in 1849 that is the oldest college in Texas still operating under its original charter. Grayson College, based in neighboring Denison, also operates a branch campus in Sherman. Notable employers in the area include Texas Instruments, Fisher Controls, Kaiser Aluminum, and the area’s largest employer, Tyson Foods.

A staple of the Texoma community, U.S. Dermatology Partners Sherman includes Board-Certified Certified Dermatologists Drs. Clint Moss, Daniel Condie, Robert Marinaro, Arathi Rana, and Certified Physician Assistant Amy Edwards. The Sherman office includes a full menu of services, including annual skin exams, the treatment of chronic skin conditions, including acne, psoriasis, and eczema, and the diagnosis and treatment of skin cancer.

To schedule an appointment at U.S. Dermatology Partners Sherman, please contact the office at (903) 892-2126 or click here to request an appointment online.

About U.S. Dermatology Partners
U.S. Dermatology Partners is one of the premier dermatology practices in the country, caring for nearly two million patients each year. With over 100 locations across eight states that span large metroplexes and rural, underserved communities, they provide the benefits of private, personalized levels of care paired with a network of coordinated, specialized dermatology physicians. U.S. Dermatology Partners is fervently focused on providing the highest level of compassionate and comprehensive patient-first care, making it seamless for all people to connect with dermatologists and national leaders in areas such as clinical research, psoriasis, and Mohs surgery, and gain access to state-of-the-art dermatological treatments, surgical and cosmetic dermatology. To learn more, visit usdermatologypartners.com.

Media Contact

Jeanne Cunningham, U.S. Dermatology Partners, 2144200655, [email protected], www.usdermatologypartners.com

SOURCE U.S. Dermatology Partners

Nierman Practice Management Unveils 2024 Dental CE Course Schedule


Nierman Practice Management (NPM) announces a new faculty lineup along with the release of its 2024 dental CE course schedule for dental sleep medicine, TMD, and medical billing in dentistry.

JUPITER, Fla., Dec. 4, 2023 /PRNewswire-PRWeb/ — Nierman Practice Management (NPM) is thrilled to announce the release of its 2024 dental CE course schedule, featuring nine engaging courses focused on dental sleep medicine, temporomandibular joint (TMJ) disorders, and medical billing in dentistry implementation.

Nierman CE courses empower dental professionals to add and grow obstructive sleep apnea (OSA) and TMJ disorders treatment into their practices. The programs also guide dentists and the dental team in navigating their patients’ medical insurance to optimize reimbursement for these services.

The diverse course line-up includes a Dental Sleep Medicine Mini-Residency, TMJ & Airway Cadaver Course, Dental Sleep Team Course, Dental Sleep Medicine Symposium, and Medical Billing in Dentistry Course.

NPM’s speaker faculty boasts leading educators and mentors, including Steve Lamberg, DDS, Anjoo Ely, DDS, Mayoor Patel, DDS, Shouresh Charkhandeh, DDS, Brijesh Chandwani, DMD, Michael Gelb, DDS, Rose Nierman, and more.

The live events are available both in-person and livestream. Most of the courses will take place at the NPM Training Center in Jupiter, FL.

President Jon Nierman encourages dental professionals to consider Jupiter not just as a learning destination but as an experience. “Our training center in Jupiter, FL, serves as a vibrant hub for Nierman CE, offering attendees the chance to enjoy breathtaking natural scenery, warm beaches, clear inlets, fishing excursions, and unique dining experiences,” says Mr. Nierman.

In addition to live continuing education, NPM offers a full online course platform for on-demand CE training and supplemental learning.

CEO Rose Nierman states, “At the core of our mission is the commitment to connect dental practices with the leading educators in dental sleep medicine, TMJ disorders, and medical billing. We strive to empower these practices for growth, enabling them to broaden their impact by treating more sleep and TMD patients, thereby transforming lives.”

For detailed information on the 2024 Nierman CE course schedule, please visit Nierman CE Schedule.

Media Contact

Milena Soriano, Nierman Practice Management, 1 5615750737, [email protected], www.NiermanPM.com

SOURCE Nierman Practice Management

A New Children’s Book, ”Gumdrops & Lollipops” by Dr. Moose, Aims to Shield Youth from the Looming Threat of Drugs


Let’s End Drug Use Among Youth!!!

TUCSON, Ariz., Dec. 4, 2023 /PRNewswire-PRWeb/ — In a world where the safety and well-being of children are paramount, Dr. Moose, a mother of four with a background in behavioral health, has penned an inspiring children’s book crafted to keep the youngest generation safeguarded from the distressing grip of fentanyl.

In today’s reality, where reports of fentanyl-related tragedies involving children continue to surface nationwide (as reported by NPR, NBC News, and Los Angeles Times), Dr. Moose’s “Gumdrops & Lollipops” takes a bold stand against this grim reality.

This compelling children’s book, precisely curated by Dr. Moose, tackles the dire issue of fentanyl exposure, gently leading children away from the clutches of this menacing drug. “Gumdrops & Lollipops” promotes critical thinking skills and provides a platform for nurturing empowerment among youth.

With a target audience including schools, teachers, parents, children, social workers, health departments, and hospitals, the book advocates a responsible, safety-first approach to combating the fentanyl crisis. The message in “Gumdrops & Lollipops” goes beyond a traditional narrative; it encourages young readers to make informed, life-preserving choices.

Kalisha Eddington, CEO of Galaxy Arizona LLC, the organization championing children’s well-being, states, “Our books provide a unique perspective on social issues impacting youth worldwide. We focus on mental health, behavioral health, assertiveness, and critical-thinking skills, cultivating children to be children, free from harm’s way.”

With the recent surge in fentanyl-related incidents involving children, the release of “Gumdrops & Lollipops” comes at a critical time. Dr. Moose’s expertise in behavioral health and her commitment to child safety make this children’s book a powerful tool in the ongoing effort to protect our youth. The book is available on Amazon and Barnes & Noble online.

For media inquiries, and interviews please contact:

Media Contact

Kalisha Eddington, Galaxy Arizona, 1 520.222.9285, [email protected], www.galaxyarizona.com

SOURCE Galaxy Arizona

First Series and Phase Change Solutions (PCS) Partner to Support UK’s Waste Reduction Goals with Apollo™ Panels


The Apollo™ Panel provides up to 7 additional hours of temperature protection during power outages and/or mechanical failures. In addition, using Apollo™ Panels reduces maintenance on refrigeration equipment while increasing product life cycle. GP practices can procure the Apollo™ Panels through Williams Medical’s website, the exclusive distributor for Apollo™ Panels in the UK.

Commenting on the partnership, Simon Gold, Principal of First Series said, “The Apollo™ Panels will be a valuable addition to our product portfolio offering assurance that product waste can be eliminated while saving energy.”

Phase Change Solutions, a leader in smart materials, is on a mission to revolutionize pharmaceutical refrigeration, reduce waste, and ensure the safe storage of medicines. PCS’ products, powered by its patented BioPCM® technology are designed to absorb and release thermal energy at precise temperatures and minimize stress on compressors in refrigerators to reduce their carbon footprint.

“We are excited to partner with First Series, introducing BioPCM® based products, in the UK. In keeping with our principles of circularity, our goal is to eliminate pharmaceutical product waste with advanced materials solutions.” He added, in addition to enabling safe management of medicine this saves time and money for GP practices.”, said Govi Rao, CEO of PCS.

About First Series:

First Series Ltd. focuses on novel commercial opportunities to help solve unmet needs in healthcare and wider industry sectors. First Series is committed to reducing the carbon footprint and environmental impact of its operations and industry partners.

About Phase Change Solutions (PCS):

Phase Change Solutions (PCS) is a global leader in the development and supply of phase change materials (“PCMs”). The company’s proprietary PCMs, collectively referred to as BioPCM® have been certified to include 100% bio-based content and listed among the USDA’s BioPreferred® products. BioPCM® can be designed to store and release thermal energy at temperatures ranging from -75C to 175C enabling customers to lower operating costs, protect perishable food & pharma and reach their sustainable development goals (SDGs).

Media Contact

Pallavi Madakasira, Phase Change Solutions, 1 336-510-4355, [email protected], https://phasechange.com/

SOURCE Phase Change Solutions